logo

SKYE

Skye Bioscience·NASDAQ
--
--(--)
--
--(--)

SKYE fundamentals

Skye Bioscience (SKYE) released its earnings on Mar 10, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.36 (YoY -50.00%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-0.36
-50.00%
Report date
Mar 10, 2026
SKYE Earnings Call Summary for Q4,2025
  • Higher Dose Expansion: Initiated 400mg/600mg IV cohorts to confirm PK/safety, with subcutaneous delivery via ENHANZE for Phase IIb.
  • Combination Efficacy: 22.3% weight loss at 52 weeks vs. 6.3% for monlunabant, with no neuropsychiatric risk.
  • APC Innovation: Unimolecular construct achieves 3-day dosing equivalence to daily combo, preserving orthogonal mechanisms.
  • Phase IIb Focus: GLP-1 experienced patients with plateaued weight loss, targeting Q4 2026 data readout.

Earnings

EPS
Revenue

Revenue & Expenses

Key Indicators

Skye Bioscience (SKYE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Skye Bioscience (SKYE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown

Balance Sheet

Skye Bioscience (SKYE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown

Cash Flow

Skye Bioscience (SKYE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown

Revenue Breakdown

Where does Skye Bioscience (SKYE) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:

Dividend

Track Skye Bioscience (SKYE) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield